NEW YORK, NY--(MARKET WIRE)--Jun 22, 2006 -- Amazon Biotech, Inc. (OTC BB:AMZBE.OB - News) (Frankfurt:B2D.F - News) announced today that it has successfully negotiated a phase I/II protocol with the FDA. This allows Amazon Biotech to move forward with implementation of its filed Phase I/II trial of its proprietary AMZ0026 therapy in HIV Positive patients.
